156 related articles for article (PubMed ID: 36382878)
1.
Božina T; Ganoci L; Karačić E; Šimičević L; Vrkić-Kirhmajer M; Klarica-Domjanović I; Križ T; Sertić Z; Božina N
Ann Hum Biol; 2022 Dec; 49(7-8):323-331. PubMed ID: 36382878
[TBL] [Abstract][Full Text] [Related]
2. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
3. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.
Soko ND; Chimusa E; Masimirembwa C; Dandara C
Pharmacogenomics J; 2019 Jun; 19(3):240-248. PubMed ID: 30100615
[TBL] [Abstract][Full Text] [Related]
4.
Rattanacheeworn P; Chamnanphon M; Thongthip S; Kittanamongkolchai W; Townamchai N; Avihingsanon Y; Udomnilobol U; Prueksaritanont T; Jianmongkol S; Chariyavilaskul P
Pharmgenomics Pers Med; 2020; 13():521-530. PubMed ID: 33122935
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
[TBL] [Abstract][Full Text] [Related]
6. The frequency of major
Alrajeh K; AlAzzeh O; Roman Y
Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
[TBL] [Abstract][Full Text] [Related]
7. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
10. Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.
Maeda A; Ando H; Ura T; Komori A; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Kobara M; Matsuzaki M; Hashimoto N; Maeda M; Kojima Y; Aoki M; Kondo E; Mizutani A; Fujimura A
Int J Clin Pharmacol Ther; 2017 May; 55(5):409-415. PubMed ID: 28157071
[TBL] [Abstract][Full Text] [Related]
11. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
12. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
13. Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.
Aklillu E; Mugusi S; Ngaimisi E; Hoffmann MM; König S; Ziesenitz V; Mikus G; Haefeli WE; Weiss J
Eur J Clin Pharmacol; 2011 Nov; 67(11):1139-45. PubMed ID: 21630030
[TBL] [Abstract][Full Text] [Related]
14. Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.
Liu M; Wu XJ; Zhao GL; Zhang T; Xu SS; Sun YX; Qiu F; Zhao LM
J Cardiovasc Pharmacol; 2016 Nov; 68(5):383-390. PubMed ID: 27557342
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
16. SLCO1B1 c.521T>C Genotyping in the Austrian Population Using 2 Commercial Real-Time Polymerase Chain Reaction Assays: An Implementation Study.
Enko D; Harringer S; Oberkanins C; Pühringer H; Halwachs-Baumann G; Kriegshäuser G
Pharmacology; 2018; 102(1-2):88-90. PubMed ID: 29969773
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
